PUMA BIOTECHNOLOGY, INC. Contracts & Agreements

Sixth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (Filed With SEC on June 24, 2024)

Seventh Amendment to Note Purchase Agreement and Third Amendment to Disclosure Letter, dated April 12, 2024, by and between the Company and Athyrium Opportunities IV CO-Invest 1... (Filed With SEC on May 2, 2024)

Sixth Amendment to Note Purchase Agreement, dated September 8, 2023, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on November 2, 2023)

Limited Waiver and Fifth Amendment to Note Purchase Agreement, dated July 7, 2023, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on August 3, 2023)

Fourth Amendment to Note Purchase Agreement, dated November29, 2022,by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on March 2, 2023)

Second Amendment to Note Purchase Agreement, dated May 18, 2022,by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on March 2, 2023)

Securities Purchase Agreement, dated December 9, 2022, by and between Puma Biotechnology, Inc. and Alan H. Auerbach (Filed With SEC on December 13, 2022)

Exclusive License Agreement, dated September 16, 2022, by and between the Company and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company... (Filed With SEC on November 3, 2022)

Third Amendment to Note Purchase Agreement, dated September 16, 2022, by and between the Company and Athyrium Opportunities IV Co-Invest 1 LP, as Administrative Agent (Filed With SEC on November 3, 2022)

First Amendment to Note Purchase Agreement, dated February 8, 2022, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (Filed With SEC on March 3, 2022)

Open Market Sale AgreementSM, dated November 4, 2021, by and between Puma Biotechnology, Inc. and Jefferies LLC (Filed With SEC on November 4, 2021)

Amendment to Warrant to Purchase Shares of Common Stock of Puma Biotechnology, Inc (Filed With SEC on June 17, 2021)

Fifth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (Filed With SEC on June 17, 2021)

Fourth Amendment to Amended and Restated Loan and Security Agreement, dated February 3, 2021, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on May 6, 2021)

Termination Agreement, dated February 24, 2021, by and between the Company and CANbridge BIOMED Limited (Filed With SEC on May 6, 2021)

Amendment No. 3 to the License Agreement, dated February 24, 2021, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 6, 2021)

Amendment No. 2 to License Agreement dated October 29, 2020, between the Company and Pfizer Inc (Filed With SEC on March 1, 2021)

Letter Agreement, dated February 13, 2020, by and between the Company and Jeff J. Ludwig (Filed With SEC on March 1, 2021)

Pfizer Letter Agreement dated June 8, 2020, by and between the Company and Pfizer Inc (Filed With SEC on August 6, 2020)

Second Amendment to Amended and Restated Loan and Security Agreement, dated July 6, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on August 6, 2020)

Third Amendment to Amended and Restated Loan and Security Agreement, dated August 5, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on August 6, 2020)

Amended Non-Employee Director Compensation Program (Filed With SEC on May 7, 2020)

First Amendment to Amended and Restated Loan and Security Agreement, dated February 27, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on March 4, 2020)

Description of the Company's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 28, 2020)

Second Amendment to the License Agreement, dated November 25, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)

First Amendment to the License Agreement, dated September 17, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)

Amendment to the License Agreement, dated December 18, 2019, by and between the Company and Knight Therapeutics, Inc (Filed With SEC on February 28, 2020)

Amended Non-Employee Director Compensation Program (Filed With SEC on November 7, 2019)

Amended and Restated Loan and Security Agreement, dated June 28, 2019, by and between the Company and Oxford Finance LLC, as collateral agent and lender (Filed With SEC on August 9, 2019)

License Agreement, dated March 29, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 10, 2019)

Side Letter Agreement, dated November 19, 2018, between the Company and CANbridge Biomed Limited (as successor in interest to CANbridgepharma Limited) (Filed With SEC on March 1, 2019)

Form of Stock Option Grant Notice and Stock Option Agreement, issued pursuant to the 2017 Employment Inducement Incentive Award Plan (Filed With SEC on March 1, 2019)

License Agreement, dated January 9, 2019, by and between the Company and Knight Therapeutics Inc (Filed With SEC on March 1, 2019)

Form Transition and General Release Agreement by and between Puma Biotechnology, Inc. and Charles R. Eyler (Filed With SEC on February 12, 2019)

Employment Offer Letter, by and between Puma Biotechnology, Inc. and Maximo F. Nougues (Filed With SEC on November 9, 2018)

Second Amendment to Loan and Security Agreement, dated September 27, 2018, by and among the Company, Silicon Valley Bank, as administrative and collateral agent and lender, and... (Filed With SEC on November 5, 2018)

First Amendment to Loan and Security Agreement, dated May 8, 2018, by and among the Company, Silicon Valley Bank, as administrative and collateral agent (Filed With SEC on August 9, 2018)

Amendment No. 1, dated April 20, 2018, to the License Agreement by and between the Company and Specialised Therapeutics Asia Pte Ltd (Filed With SEC on August 9, 2018)

Supply Agreement, dated April 20, 2018, by and between the Company and Specialised Therapeutics Asia Pte. Ltd (Filed With SEC on August 9, 2018)

Amended Non-Employee Director Compensation Program (Filed With SEC on August 9, 2018)

License Agreement, dated March 30, 2018, between the Company and Pint Pharma International SA (Filed With SEC on May 10, 2018)

Collaboration and License Agreement, dated January 30, 2018, between the Company and CANbridgepharma Limited (Filed With SEC on May 10, 2018)

License Agreement, dated November 20, 2017, by and between the Company and Specialised Therapeutics Asia Pte Ltd (Filed With SEC on March 9, 2018)

Loan and Security Agreement dated October 31, 2017, by and among the Company, Silicon Valley Bank, as administrative and collateral agent, and the lenders party thereto from time... (Filed With SEC on March 9, 2018)

Letter Agreement, dated December 8, 2017, between the Company and Douglas Hunt (Filed With SEC on March 9, 2018)

Puma Biotechnology, Inc. Non-Employee Director Compensation Program (Filed With SEC on August 9, 2017)

FOURTH AMENDMENT TO PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN (Filed With SEC on June 14, 2017)

THIRD AMENDMENT TO PUMABIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN (Filed With SEC on June 14, 2017)

PUMA BIOTECHNOLOGY, INC. (aDelaware corporation) 3,750,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 21, 2016)

PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE (Filed With SEC on October 17, 2016)

10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024 ###-###-#### Phone ###-###-#### Fax (Filed With SEC on August 9, 2016)

Puma Biotechnology, Inc. Non-Employee Director Compensation Program (Effective January 21, 2016) (Filed With SEC on February 29, 2016)

FOURTH AMENDMENT (Filed With SEC on November 9, 2015)

THIRD AMENDMENT TO LEASE (Filed With SEC on November 9, 2015)

10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024 ###-###-#### Phone ###-###-#### Fax (Filed With SEC on November 9, 2015)

SECOND AMENDMENT TO PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN (Filed With SEC on August 10, 2015)

SECOND AMENDMENT TO LEASE (Filed With SEC on August 10, 2015)

THIRD AMENDMENT (Filed With SEC on March 2, 2015)

PUMA BIOTECHNOLOGY, INC. (a Delaware corporation) 1,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 22, 2015)

Amendment No. 1 to License Agreement between Puma Biotechnology, Inc. and Pfizer Inc. (Filed With SEC on November 10, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on May 23, 2014)

PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN PERFORMANCE SHARE AWARD GRANT NOTICE (Filed With SEC on March 3, 2014)

SECOND AMENDMENT (Filed With SEC on March 3, 2014)

PUMA BIOTECHNOLOGY, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Filed With SEC on March 3, 2014)

FIRST AMENDMENT (Filed With SEC on April 1, 2013)

PUMA BIOTECHNOLOGY, INC. (a Delaware corporation) 7,500,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 24, 2012)

PUMA BIOTECHNOLOGY, INC. (a Delaware corporation) lShares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 15, 2012)

INDEMNIFICATION AGREEMENT (Filed With SEC on October 15, 2012)

10880 Wilshire Blvd. Suite 2150 Los Angeles,California 90024 ###-###-#### Phone ###-###-#### Fax (Filed With SEC on June 26, 2012)

OFFICE LEASE BY AND BETWEEN DWF III GATEWAY, LLC, A Delaware limited liability company, As Landlord And PUMA BIOTECHNOLOGY, INC., A Delaware corporation, as Tenant For Leased... (Filed With SEC on June 13, 2012)

PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT (Filed With SEC on March 29, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on January 24, 2012)

LICENSE AGREEMENT (Filed With SEC on December 16, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 16, 2011)

PUMA BIOTECHNOLOGY, INC. REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 16, 2011)

OFFICE LEASE (Filed With SEC on December 13, 2011)

PUMA BIOTECHNOLOGY, INC. SUBSCRIPTION AGREEMENT (Filed With SEC on November 23, 2011)

AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 23, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 18, 2011)

PUMA BIOTECHNOLOGY, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK (Filed With SEC on October 11, 2011)

LICENSE AGREEMENT (Filed With SEC on October 11, 2011)

REDEMPTION AGREEMENT (Filed With SEC on October 11, 2011)

PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE (Filed With SEC on October 11, 2011)

PUMA BIOTECHNOLOGY, INC. REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 11, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on October 11, 2011)

INDEMNITY AGREEMENT (Filed With SEC on October 4, 2011)

AGREEMENT AND PLAN OF MERGER by and among Puma Biotechnology, Inc. Innovative Acquisitions Corp. and IAC Merger Corporation September 29, 2011 TABLE OF CONTENTS (Filed With SEC on October 4, 2011)

Category

Industry

Companies

Contracts

PUMA BIOTECHNOLOGY, INC. Contracts & Agreements